In addition, the significant correlation between lncRNA-MEG3, CXCL13, miR-125a-5p, and NF-kB might suggest a novel molecular pathway in patients with ITP that starts with lncRNA-MEG3 overexpression that decreases miR-125a-5p expression, leading to increased CXCL13 probably through the NF-kB pathway which could be provide a new therapeutic target in the management of ITP. This evidence concerns the gene NFKB1 and autoimmune thrombocytopenic purpura.